SLC2A1 and rheumatoid arthritis: The hypoxic microenvironment in some autoimmune diseases upregulates the GLUT1 expression by either T-cell-specific knockouts or small-molecule GLUT1/glycolysis inhibitors, by which improvement can be seen in arthritis rheumatoid, lupus, or psoriasis [108].